USAQ QHSLab Inc (QB)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of report (date of earliest event reported): February 11, 2025

 

QHSLab, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

0-19041

(Commission File No.)

 

Nevada		30-1104301
(State of Incorporation)		(I.R.S. Employer Identification No.)
901 Northpoint Parkway Suite 302 West Palm Beach FL 33407		33407
(Address of Principal Executive Offices)		(ZIP Code)

 

Registrant’s telephone number, including area code: (929) 379-6503

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)

 

Securities registered pursuant to Section 12(g) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value		USAQ		N/A

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On February 11, 2025 QHSLab, Inc. (the “Company,” OTCQB: USAQ), issued a press release announcing QHSLab and Town Total Compounding’s strategic co-marketing partnership to expand market opportunities and drive organic growth. The full text of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in this Current Report on Form 8-K (including the exhibit) is furnished pursuant to Item 7.01 and shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information in the Report that is required to be disclosed solely by Regulation FD.

 

We do not have, and expressly disclaim, any obligation to release publicly any updates or any changes in our expectations or any change in events, conditions, or circumstances on which any forward-looking statement is based.

 

We use, and will continue to use, our website (https://usaqcorp.com), press releases, and various social media channels, including our Twitter account (https://twitter.com/qhslabinc), LinkedIn account (https://www.linkedin.com/company/65407282/), Facebook account (https://www.facebook.com/QHSLabs) and Instagram account (https://www.instagram.com/qhslabs/) as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information we post on our website, disseminate in press releases and on social media could be deemed to be material information, and we encourage investors, the media and others interested in the Company to review the business and financial information that we post on our website, disseminate in press releases and on the social media channels identified above, as such information could be deemed to be material information.

 

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

 

(d) Exhibits.

 

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No.		Description
99.1		Press Release dated February 11, 2025 – QHSLab and Town Total Compounding Announce Strategic Co-Marketing Partnership to Expand Market Opportunities and Drive Organic Growth
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

SIGNATURES

 

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the Registrant has duly caused this current report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: February 11, 2025
QHSLab, Inc.
	/s/ Troy Grogan
Name:	Troy Grogan
Title:	CEO and Chairman

 

 

Exhibit 99.1

 

 

QHSLab and Town Total Compounding Announce Strategic Co-Marketing Partnership to Expand Market Opportunities and Drive Organic Growth

 

	●	Expanding market reach to drive organic revenue growth without equity dilution
	●	Collaborating with AI-driven health assessments and customized pharmacy solutions to enhance patient care.
	●	Integrating Digital Health & Compounded Medications to bridge the gap between digital screening tools and patient-specific pharmaceutical treatments.
	●	Bringing Scalable, Data-Driven Healthcare to 200+ Primary Care Practices

 

WEST PALM BEACH, FL, February 11, 2025 (GLOBE NEWSWIRE) — QHSLab Inc. (“the Company”) (OTCQB: USAQ), a leading provider of digital healthcare solutions and diagnostic technologies, has entered into a strategic co-marketing partnership with Town Total Compounding to expand market opportunities and enhance patient care through a comprehensive, integrated approach. This collaboration will introduce QHSLab’s Integrated Service Program (ISP) to over 200 primary care medical practices within Town Total’s network, aligning digital medicine assessments with personalized prescription therapies for GLP-1s, Hormone Replacement Therapy (HRT), Allergen Immunotherapy, Pain Management, and Dermatological treatments.

 

By leveraging QHSLab’s digital medicine technology and Town Total’s expertise in patient-specific compounding, this mutually supportive partnership offers a non-dilutive growth opportunity for both organizations while expanding access to cutting-edge healthcare solutions.

 

A Non-Dilutive, Scalable Growth Strategy

 

This co-marketing initiative underscores both companies’ commitment to expanding market reach without requiring additional capital investment. By integrating QHSLab’s digital health capabilities into Town Total’s established provider relationships, the partnership fosters organic business growth, enhances provider engagement, and drives better patient adherence and treatment outcomes.

 

Enhancing Patient Outcomes with Integrated Care

 

QHSLab’s digital screening and assessment tools empower physicians with AI-driven insights and patient engagement resources, seamlessly integrating with Town Total Compounding’s ability to tailor treatments to individual patient needs. The partnership ensures a holistic approach to healthcare, optimizing both pharmacological and behavioral health interventions for better long-term patient outcomes.

 

“At Town Total Compounding, our mission is to help keep patients healthy by delivering personalized, high-quality medications,” said Joseph Navarra, R.Ph., FACA, Head of Pharmacy and Owner of Town Total Compounding Center. “This collaboration with QHSLab allows us to offer primary care providers a seamless way to integrate digital medicine into their patient care plans, ensuring tailored treatment strategies that enhance clinical effectiveness.”

 

“QHSLab’s partnership with Town Total represents a significant step forward in combining digital health innovation with customized pharmacy solutions,” said Troy Grogan, CEO of QHSLab, Inc. “By providing primary care practices with advanced screening tools alongside specialized compounding services, we are creating a scalable, patient-centered approach to improving health outcomes—without the need for external financing or equity dilution.”

 

For more information about QHSLab and our healthcare solutions, please visit www.qhslab.com.

 

 

About QHSLab, Inc.

 

QHSLab, Inc. (OTCQB: USAQ) is a medical device company providing digital healthcare solutions and point-of-care-diagnostic tests to primary care physicians. Digital healthcare allows doctors to assess patient responses quickly and effectively using advanced artificial intelligence algorithms. Digital healthcare can also remotely monitor patients’ vital signs and evaluate the effects of prescribed medicines and treatments on patients’ health through real-time data transferred from patient to doctor. QHSLab, Inc. also markets and sells point-of-care, rapid-response diagnostic tests used in the primary care practice. QHSLab, Inc.’s products and services are designed to help physicians improve patient monitoring and medical care while also increasing their revenues.

 

About Town Total Compounding Center Town Total Compounding Center, based in Woodbury, NY, is a PCAB-accredited pharmacy specializing in sterile and non-sterile compounding. With over 30 years of experience, Joseph Navarra, R.Ph., FACA, FAPC has led the pharmacy’s commitment to customized patient care, serving prominent institutions such as NYU, Mount Sinai, and Montefiore Medical Center.

 

Forward-Looking Statements

 

Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

 

Investor Relations Contact:

 

Brett Maas, Managing Principal, Hayden IR, LLC

brett@haydenir.com

646-536-7331

https://twitter.com/QHSLabInc

 

v3.25.0.1

Cover	Feb. 11, 2025
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Feb. 11, 2025
Entity File Number	0-19041
Entity Registrant Name	QHSLab, Inc.
Entity Central Index Key	0000856984
Entity Tax Identification Number	30-1104301
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	901 Northpoint Parkway
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33407
City Area Code	(929)
Local Phone Number	379-6503
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $0.0001 par value
Trading Symbol	USAQ

---